Referencias:

              

1.      Connie Sanchez, Karen E. Asin  & Francesc Artigas. “Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data”. Pharmacology & Therapeutics. 1-15.

2.      Arne Mørk, Liliana P. Montezinho, Silke Miller, Crista Trippodi-Murphy, Niels Plath, Yan Li, Maria Gulinello & Connie Sanchez. “Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats”. Pharmacology, Biochemistry and Behavior. 105 (2013):41–50.

3.      Per Stenkrona, Christer Halldin & Johan Lundberg. “5-HTT and5-HT1A receptor occupancyofthe novel substancevortioxetine(LuAA21004). A PETstudyincontrolsubjects”. European Neuropsychopharmacology. 23 (2013): 1190–1198.

4.      Jean-Philippe Guilloux, Indira Mendez-David, Alan Pehrson, Bruno P. Guiard, Christelle Repérant, Sophie Orvoën, Alain M. Gardier, René Hen, Bjarke Ebert, Silke Miller, Connie Sanchez, Denis J. David. “Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice”. Neuropharmacology. 73 (2013): 147-159.

5.      Alan L. Pehrson, Steven C. Leiser, Maria Gulinello, Elena Dale, Yan Li, Jessica A. Waller & Connie Sanchez. “Treatmentofcognitivedysfunctioninmajordepressivedisorder -a reviewofthepreclinicalevidenceforefficacy ofselectiveserotonin reuptakeinhibitors,serotonin- norepinephrinereuptakeinhibitors and themultimodal actingantidepressantvortioxetine”. European Journal of Pharmacology. (2013).

6.      Leszek Bidzan, Atul R. Mahableshwarkar, Paula Jacobsen, Mingjin Yan & David V. Sheehan. “Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial”. European Neuropsychopharmacology. 22 (2012): 847–857.

7.      Akiko Nagane, Hajime Baba, Yoshiyuki Nakano, Hitoshi Maeshima, Mana Hukatsu, Kazuhiro Ozawa, Toshihito Suzuki & Heii Arai. “Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression: Class-specific influence by tricyclic antidepressants and newer antidepressants”. Psychiatry Research  . 218 (2014): 101–105.

8.      Andrew Gibb & Emma D. Deeks. “Vortioxetine: First Global Approval”. R & D Insight Report (2013)

9.      Zheli CHEN, Guanghua ZAN, Xinhua SHEN, Xingen PAN, Xiaoxun CHEN & Jianhua Ll. “ Relationship of changes in cognitive and depressive symptoms during antidepressant treatment of individual with geriatric depression and their relationship to the APOE epsilon 4 allele”. Shangai Archieves of Psychiatry. 25 (2013): 99-106.

10.  Roger S. McIntyre, MD,  Danielle S. Cha, HBSc, Joanna K. Soczynska, HBSc, Hanna O. Woldeyohannes, HBSc, Laura Ashley Gallaugher, HBSc,2 Paul Kudlow, BSc, MD, Mohammad Alsuwaidan, MD, MPH, FRCPC, Dip ABPN, & Anusha Baskaran, HBSc, MSc: “Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions”. depression and anxiety 30(2013): 515–527

Otras referencias:

1.                  National Institute of Mental Health. Depression. Bethesda: National Institute of Mental Health Science Writing, Press & Dissemination Branch, 2008.